Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Adult
Aged
Anemia, Aplastic
/ drug therapy
Antilymphocyte Serum
/ adverse effects
Benzoates
/ adverse effects
Cyclosporine
/ adverse effects
Drug Eruptions
/ etiology
Female
Gingival Hypertrophy
/ chemically induced
Hirsutism
/ chemically induced
Humans
Hydrazines
/ adverse effects
Immunosuppressive Agents
/ adverse effects
Male
Middle Aged
Pyrazoles
/ adverse effects
Retrospective Studies
Tacrolimus
/ adverse effects
Aplastic anemia
Cyclosporine
Eltrombopag
Immunosuppressive therapy
Tacrolimus
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
28
03
2020
accepted:
03
01
2021
pubmed:
10
1
2021
medline:
26
3
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
First-line treatment of aplastic anemia(AA) and for AA patients ineligible for hematopoietic stem cell transplantation (HSCT) has consisted of antithymocyte globulin (ATG), the calcineurin inhibitor cyclosporine A (CsA), and more recently eltrombopag. However, at our institution, we have successfully substituted another calcineurin inhibitor, tacrolimus, as a part of immunosuppressive threatment (IST) for AA due to more favorable toxicity profile. Since there is limited data on the use of tacrolimus in aplastic anemia, we conducted a retrospective review of twenty patients treated with tacrolimus-based immunosuppressive therapy (IST) as a first- or second-line treatment. The overall response rate was comparable to that of patients treated with CsA (18 patients). However, there were no cutaneous side effects observed in patients receiving tacrolimus, a relatively common finding with CsA use. Our data suggest that tacrolimus-based IST is a potential option in AA and might have a more favorable toxicity profile compared to CsA.
Identifiants
pubmed: 33420879
doi: 10.1007/s00277-021-04401-6
pii: 10.1007/s00277-021-04401-6
pmc: PMC7960622
doi:
Substances chimiques
Antilymphocyte Serum
0
Benzoates
0
Hydrazines
0
Immunosuppressive Agents
0
Pyrazoles
0
Cyclosporine
83HN0GTJ6D
eltrombopag
S56D65XJ9G
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-939Références
Townsley DM et al (2017) “Eltrombopag added to standard immunosuppression for aplastic anemia,” (in eng). N Engl J Med 376(16):1540–1550. https://doi.org/10.1056/NEJMoa1613878
doi: 10.1056/NEJMoa1613878
pubmed: 28423296
pmcid: 5548296
Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young NS (2011) “Horse versus rabbit antithymocyte globulin in acquired aplastic anemia,” (in eng). N Engl J Med 365(5):430–438. https://doi.org/10.1056/NEJMoa1103975
doi: 10.1056/NEJMoa1103975
pubmed: 21812672
pmcid: 3721503
Boddu PC, Kadia TM (2017) “Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review,” (in eng). Expert Rev Hematol 10(5):433–448. https://doi.org/10.1080/17474086.2017.1313700
doi: 10.1080/17474086.2017.1313700
pubmed: 28452257
Bacigalupo A (2017) “How I treat acquired aplastic anemia,” (in eng). Blood 129(11):1428–1436. https://doi.org/10.1182/blood-2016-08-693481
doi: 10.1182/blood-2016-08-693481
pubmed: 28096088
Tisdale JF, Dunn DE, Maciejewski J (Jan 2000) Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. (in eng), Semin Hematol 37(1):102–109
doi: 10.1016/S0037-1963(00)90034-9
Muduma G, Saunders R, Odeyemi I, Pollock RF (2016) Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. (in eng), PLoS One 11(11):e0160421. https://doi.org/10.1371/journal.pone.0160421
doi: 10.1371/journal.pone.0160421
Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C (Dec 2010) Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. (in eng), Eur J Clin Pharmacol 66(12):1177–1187. https://doi.org/10.1007/s00228-010-0902-6
doi: 10.1007/s00228-010-0902-6
Penninga L, Wettergren A, Chan AW, Steinbrüchel DA, Gluud C (2012) Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. (in eng), Cochrane Database Syst Rev (3):CD008852. https://doi.org/10.1002/14651858.CD008852.pub2
Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C (2013) Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. (in eng), Cochrane Database Syst Rev (5):CD008817. https://doi.org/10.1002/14651858.CD008817.pub2
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. (in eng), BMJ 331(7520):810. https://doi.org/10.1136/bmj.38569.471007.AE
doi: 10.1136/bmj.38569.471007.AE
Inamoto Y, Flowers MED, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OTH, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015) Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. (in eng), Biol Blood Marrow Transplant 21(10):1776–1782. https://doi.org/10.1016/j.bbmt.2015.05.023
doi: 10.1016/j.bbmt.2015.05.023
Wiederrecht G, Lam E, Hung S, Martin M, Sigal N (Nov 1993) “The mechanism of action of FK-506 and cyclosporin A,” (in eng). Ann N Y Acad Sci 696:9–19
doi: 10.1111/j.1749-6632.1993.tb17137.x
Mukherjee S, Mukherjee U (2009) “A comprehensive review of immunosuppression used for liver transplantation,” (in eng). J Transp Secur 2009:701464–701420. https://doi.org/10.1155/2009/701464
doi: 10.1155/2009/701464
Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T (2009) Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. (in eng), Pediatr Blood Cancer 52(5):626–630. https://doi.org/10.1002/pbc.21926
doi: 10.1002/pbc.21926
Macartney C, Freilich M, Odame I, Charpentier K, Dror Y (2009) Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. (in eng), Pediatr Blood Cancer 52(4):525–527. https://doi.org/10.1002/pbc.21751
doi: 10.1002/pbc.21751
Zhu X, Guan J, Xu J, Wei J, Jiang L, Yin J, Zhao L, Zhang Y (2014) Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. (in eng), Blood Cells Mol Dis 53(3):157–160. https://doi.org/10.1016/j.bcmd.2014.04.008
doi: 10.1016/j.bcmd.2014.04.008
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G, European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party (2012) Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. (in eng), Blood 119(23):5391–5396. https://doi.org/10.1182/blood-2012-02-407684
doi: 10.1182/blood-2012-02-407684
Shetty M, Narendra AM, Adiraju KP, Modugu NR (2016) Study of aplastic anaemia with cyclosporine in resource poor setting. (in eng), J Clin Diagn Res 10(6):OC15–OC18. https://doi.org/10.7860/JCDR/2016/16144.7952
doi: 10.7860/JCDR/2016/16144.7952
Gluckman E et al (1992) Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. (in eng), Blood 79(10):2540–2546
Ilyas M, Colegio OR, Kaplan B, Sharma A (2017) Cutaneous toxicities from transplantation-related medications. (in eng), Am J Transplant 17(11):2782–2789. https://doi.org/10.1111/ajt.14337
doi: 10.1111/ajt.14337
Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. (in eng), Transplantation 100(8):1723–1731. https://doi.org/10.1097/TP.0000000000001243
doi: 10.1097/TP.0000000000001243
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JCW, the British Society for Standards in Haematology (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. (in eng), Br J Haematol 172(2):187–207. https://doi.org/10.1111/bjh.13853
doi: 10.1111/bjh.13853
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. (in eng), N Engl J Med 367(1):11–19. https://doi.org/10.1056/NEJMoa1200931
doi: 10.1056/NEJMoa1200931
Chiu V, Weitz IC, Hermel DJ (2017) Tacrolimus is effective immunosuppressive therapy in aplastic anemia. In: Blood : Journal of the American Society of Hematology, vol 130, ed.
Cheng H, Wang X, Zhou D, Cao J, Larochelle A, Xu KL (2019) Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. (in eng), Ann Hematol 98(8):2009–2011. https://doi.org/10.1007/s00277-019-03658-2
doi: 10.1007/s00277-019-03658-2
Scheinberg P (2018) Activity of eltrombopag in severe aplastic anemia. (in eng), Hematology Am Soc Hematol Educ Program 2018(1):450–456. https://doi.org/10.1182/asheducation-2018.1.450
doi: 10.1182/asheducation-2018.1.450
Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf-Neto J, Falcao RP, Lorand-Metze IG, Goldenberg D, Santana CL, de Oliveira Werneck Rodrigues D, Passos LNM, Rosenfeld LGM, Pitta M, Loggetto S, Feitosa Ribeiro AA, Velloso ED, Kondo AT, de Miranda Coelho EO, Pintao MCT, de Souza HM, Borbolla JR, Pasquini R (2009) Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. (in eng), Haematologica 94(9):1220–1226. https://doi.org/10.3324/haematol.2008.002642
doi: 10.3324/haematol.2008.002642